OMB’s proposed grantmaking rule will destabilize biomedical research, experts warn
Biomedical research groups have warned that a proposed US Office of Management and Budget rule could make federal research funding less predictable by increasing political control over grant decisions and allowing grants to be ended more easily. They argue this could disrupt long-term studies, discourage scientific collaboration and slow the development of treatments, while supporters say the changes would strengthen oversight and ensure grants reflect administration priorities.
The proposal would overhaul the government-wide rules governing federal grants, affecting how awards are reviewed, managed and terminated. Critics highlight provisions that would make peer review advisory, require awards to advance the President’s policy priorities, restrict some international collaborations and limit funding for publication or conference costs; the public consultation closed on 13 July 2026, with the rule proposed to take effect on 1 October.
- Scientists fear political control could destabilise federal biomedical research.
- Peer review could lose influence over grant decisions.
- The proposal would reshape grants across US federal agencies.
New here? Start with this
The US Office of Management and Budget (OMB) sets rules for how federal agencies award and manage grants, including money for biomedical research. Many studies rely on government grants to pay researchers, run experiments and share findings over several years.
Research awards are often assessed by other scientists through peer review, which helps agencies judge their quality and value. The proposed changes would affect how much that review guides decisions, what policy goals grants must serve, and when funding can be ended.
The debate matters because biomedical research can take years, and changes to funding can affect ongoing studies and work across institutions or countries. Supporters say stronger oversight would align grants with the administration’s priorities; critics say greater uncertainty could make long-term research and collaboration harder to sustain.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Government has a legitimate interest in aligning federal research spending with democratically determined priorities and administration objectives. Proponents argue that stronger oversight mechanisms and requirements for grants to reflect policy goals constitute responsible stewardship of public funds, ensuring that taxpayer investment serves identified national priorities whilst maintaining professional grant management and accountability standards.
The case against
Scientific progress depends fundamentally on merit-based peer review and research independence from political influence. Critics argue that subordinating grant decisions to policy alignment risks compromising research quality and innovation; that restrictions on international collaboration weaken science when progress is increasingly global; and that destabilised funding threatens long-term research programmes where breakthroughs require years of continuity, potentially driving leading researchers and talent overseas.